Nothing Special   »   [go: up one dir, main page]

Guillaumin et al., 2022 - Google Patents

Safety profile of repeated infusion of platelet-like nanoparticles in healthy dogs

Guillaumin et al., 2022

View PDF
Document ID
9143090648404184529
Author
Guillaumin J
Satchell P
Yaxley P
Bruckman M
Gupta A
Publication year
Publication venue
American journal of veterinary research

External Links

Snippet

OBJECTIVE To assess the safety and efficacy of the platelet-like nanoparticle (PLN), and to assess its safety in repeated administration. ANIMALS 6 purpose-bred dogs. PROCEDURES The PLN was administered IV at 3 different doses using a randomized …
Continue reading at avmajournals.avma.org (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated

Similar Documents

Publication Publication Date Title
Horrow et al. Prophylactic tranexamic acid decreases bleeding after cardiac operations
CN101072506B (en) Methods of making freeze-dried platelets, compositions comprising freeze-dried platelets and methods of use
Kececi et al. A cost-effective method for obtaining standard platelet-rich plasma
JP2011184465A (en) Fibrinogen targetting microparticle for promoting hemostasis
JPS58500994A (en) Pharmaceutical composition for hemostasis
Nishikawa et al. Fibrinogen γ‐chain peptide‐coated, ADP‐encapsulated liposomes rescue thrombocytopenic rabbits from non‐compressible liver hemorrhage
WO2021046409A1 (en) Materials and methods for blood plasma preparations
WO2020186193A1 (en) Canine blood platelet preparations
Lassila et al. Mast cell–derived heparin proteoglycans as a model for a local antithrombotic
US20100226902A1 (en) Method For Treating Wounds With Enriched Platelet Wound Healant
JP2007507480A5 (en)
Saxonhouse et al. Platelet function in term and preterm neonates
Guillaumin et al. Safety profile of repeated infusion of platelet-like nanoparticles in healthy dogs
Cases et al. In vivo evaluation of platelet activation by different cellulosic membranes
Plewa et al. Hematologic safety of intraosseous blood transfusion in a swine model of pediatric hemorrhagic hypovolemia
EP3400029B1 (en) Compositions for reducing tissue adhesions
US20160045573A1 (en) Nanoparticles with effects on endothelial function and membrane permeability
Schmid et al. Low-dose recombinant factor VIIa for massive bleeding: a single centre observational cohort study with 73 patients.
McMillan et al. Acquired coagulation disorders in children
Sloand et al. Effect of amphotericin B and fluconazole on platelet membrane glycoproteins
Koch et al. Impaired bacterial clearance after activation of the complement and coagulation systems
Myers et al. A multicenter investigation into the occurrence of high-pressure excursions
JP2012519674A (en) New use of fibrinogen
Acharya et al. Photothrombolytics: A light-driven technology for the targeted lysis of thrombi
Sonegaonkar et al. BIOTINYLATED ERYTHROCYTES-A NOVEL DRUG DELIVERY SYSTEM